JAK1 and neoplasm: We investigated the prevalence of those mutations before ICB by collating data from The Cancer Genome Atlas (TCGA) for pre-treatment tumours which harboured mutations in the IFNγ receptor subunits (IFNGR1/2) or downstream signalling molecules (JAK1/2, STAT1).